Step-up fecal microbiota transplantation strategy: A pilot study for steroid-dependent ulcerative colitis

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Cui, Bota ^a   Li, Pan ^a   Xu, Lijuan ^a   Zhao, Youquan ^b   Wang, Huiquan ^c   Peng, Zhaoyuan ^a   Xu, Hai'e ^a   Xiang, Jie ^a   He, Zhi ^a   Zhang, Ting ^a   Nie, Yongzhan ^d   Wu, Kaichun ^d   Fan, Daiming ^d   Ji, Guozhong ^a   Zhang, Faming ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c TIANJIN POLYTECHNIC UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Microbiota; Step up fecal microbiota transplantation strategy; Steroid dependent ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; MESALAZINE; PREDNISONE; RNA 16S; CORTICOSTEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; BIOLOGICAL THERAPY; CHILD; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DONOR; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FOLLOW UP; HUMAN; INTESTINE FLORA; LEUKOCYTE; LYMPHOCYTE; MALE; MICROBIAL COMMUNITY; MIDDLE AGED; OBSERVATIONAL STUDY; PATIENT SAFETY; PILOT STUDY; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; REMISSION; RNA SEQUENCE; SCHOOL CHILD; SPECIES COMPOSITION; STEP UP FECAL MICROBIOTA TRANSPLANTATION; STEROID DEPENDENT ULCERATIVE COLITIS; STEROID THERAPY; SYMPTOM; TREATMENT RESPONSE; ULCERATIVE COLITIS; YOUNG ADULT; ADOLESCENT; COLITIS, ULCERATIVE; FECAL MICROBIOTA TRANSPLANTATION; FECES; MICROBIOLOGY; MICROFLORA; SPECIMEN HANDLING; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CHILD; COLITIS, ULCERATIVE; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SPECIMEN HANDLING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941273178     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0646-2     Document Type: Article

References (33)

1. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-63.
2. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-7.
3. Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-32.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
5. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Flejou JF, Herfarth H, Hommes DW, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23.
6. Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther. 2013;38:77-97.
7. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-72.
8. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2014;20:1368-74.
9. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755.
10. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:597-601.
11. Brandt L, Aroniadis O. Long-term follow-up study of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). Am J Gastroenterol. 2012;107:S657.
12. Borody T, Wettstein A, Campbell J, Leis S, Torres M, Finlayson S, Nowak A. Fecal microbiota transplantation in ulcerative colitis: review of 24 years experience. Am J Gastroenterol. 2012;107:S665.
13. Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51-8.
14. Gordon H, Harbord M. A patient with severe Crohn's colitis responds to faecal microbiota transplantation. J Crohns Colitis. 2014;8:256-7.
15. Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol. 2013;19:7213-6.
16. Kao D, Hotte N, Gillevet P, Madsen K. Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol. 2014;48:625-8.
17. Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol. 2015;21:5359-71.
18. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-15.
19. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.
20. Dubberke ER, Burdette SD. Clostridium difficile infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):42-9.
21. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-9.
22. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-71.
23. Brandt L, Aroniadis O, Greenberg A, Borody T, Finlayson S, Furnari V, Kelly C. Safety of fecal microbiota transplantation (FMT) in immunocompromised (Ic) patients with inflammatory bowel disease (IBD). Am J Gastroenterol. 2013;108:S556.
24. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1569-81.
25. Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19:2155-65.
26. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036-8.
27. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47:735-7.
28. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
29. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol. 2012;9:219-30.
30. Chinen T, Rudensky AY. The effects of commensal microbiota on immune cell subsets and inflammatory responses. Immunol Rev. 2012;245:45-55.
31. Gorkiewicz G, Thallinger GG, Trajanoski S, Lackner S, Stocker G, Hinterleitner T, Gully C, Hogenauer C. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One. 2013;8:e55817.
32. Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, Zanini A, Chebli JM. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-9.
33. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollon F, Hauser W, Herrlinger K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1-33.